COMBINATION VACCINES AGAINST CORONAVIRUS INFECTION, INFLUENZA INFECTION, AND/OR RSV INFECTION

VARIANT STRAIN-BASED CORONAVIRUS VACCINES

DEVELOPMENT OF MULTI-ANTIGEN MRNA VACCINE AGAINST FELINE FIPV

METHOD FOR CONSTRUCTING CIRCULAR RNA AND VACCINE AGAINST FIPV

PAN-SARBECOVIRUS NANOPARTICLE VACCINES

NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF

IMMUNOGENIC COMPOSITIONS AGAINST THE OMICRON VARIANT OF SEVERE ACUTE RESPITORY SYNDROME CORONAVIRUS 2 (SARS-COV-2)

TREATMENT USING A ONE-TO-STOP ATTENUATED SARS-COV-2 VIRUS

VACCINES

THERAPEUTIC DRUG COMBINATIONS FOR TREATING, AMELIORATING OR PREVENTING CORONAVIRUS INFECTION

BETACORONAVIRUS mRNA VACCINES

CORONAVIRUS VACCINE FORMULATIONS

BETACORONAVIRUS mRNA VACCINES

COMBINATION CONTAINING AN MRNA VACCINE OR AN MRNA ENCODED THERAPEUTIC PROTEIN AND AN IMMUNE MODULATING MRNA FOR IMPROVED OR REDUCED IMMUNOGENICITY TO INCREASE EFFICACY

MODULAR BACTERIOPHAGE T4 NANOPARTICLE PLATFORM ENABLES RAPID DESIGN OF DUAL COVID-19-FLU MUCOSAL VACCINES

IMMUNIZATION METHOD AGAINST INFECTION BY SARS-CoV-2

MULTIVALENT CARRIERS AND RELATED VACCINE COMPOSITIONS

KARI Nanoparticle

COMPOSITIONS AND METHODS COMPRISING LIPID NANOPARTICLE VACCINES THAT ELICIT A MODULATED IMMUNE RESPONSE

CORONAVIRUS SPIKE PROTEIN-BASED VACCINES

COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSES

PEPTIDE-LOADED ANTIGEN PRESENTING CELL-DERIVED EXTRACELLULAR BLEBS AS A MOLECULARLY TARGETED VACCINE

NUCLEIC ACID VACCINES ENCAPSULATED WITH NANOALUMINOSILICATE AGAINST MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS (MERS-CoV)

METHOD FOR MANUFACTURING INACTIVATED SARS-COV-2 VACCINE, INACTIVATED SARS-COV-2 VACCINE, METHOD FOR PURIFYING SARS-COV-2 OR INACTIVATED SARS-COV-2, AND SARS-COV-2 ANTIGEN COMPOSITION OR INACTIVATED SARS-COV-2 ANTIGEN COMPOSITION

PHARMACEUTICAL COMPOSITION FOR RESISTING INFECTION WITH SARS-COV-2 OR MUTANT THEREOF, AND COMBINED DRUG THEREOF

COVID19 mRNA Vaccine

THERMOSTABLE MUCOSAL VACCINE COMPOSITIONS AND METHODS

FUSION PROTEIN AND VACCINE

VIRUS-LIKE VESICLES (VLVS) BASED VACCINES AND METHODS OF PREVENTING, AMELIORATING, AND/OR TREATING COVID-19 AND/OR HEPATOCELLULAR CARCINOMA (HCC)

VACCINE COMPOSITION FOR SUBLINGUAL ADMINISTRATION

VACCINE PLATFORM

MRNA FOR SARS-COV-2 S PROTEIN AND USE THEREOF

SARS-COV-2 VACCINE BOOSTER COMPOSITION

NEW MERS-COV VACCINE

SELF-REPLICATING RNA VACCINES AND METHODS OF USE

SARS-COV-2 LACKING THE ENVELOPE PROTEIN AS AN ATTENUATED VACCINE VIRUS AGAINST COVID-19

Coronavirus Spike Glycoprotein With Improved Expression and Stability

RECOMBINANT VECTOR FOR EXPRESSING IMMUNOGENIC PROTEIN OF PORCINE EPIDEMIC DIARRHEA VIRUS (PEDV), RECOMBINANT STRAIN INCLUDING THE SAME, AND USE THEREOF

RECOMBINANT VACCINE AGAINST COVID-19 TO PRODUCE CELLULAR RESPONSE IN INDIVIDUALS WITH PRE-EXISTING IMMUNITY

CROSS-REACTIVE CORONAVIRUS SPIKE PROTEIN AND METHODS OF USE THEREOF

VARIANT STRAIN-BASED CORONAVIRUS VACCINES

VACCINE COMPOSITIONS AND USES THEREOF

METHODS TO INCREASE IMMUNOGENICITY OF RDRP

CORONAVIRUS IMMUNOGEN COMPOSITIONS AND THEIR USES

NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGEN

SARS-CoV-2 Vaccine Constructs

ADENOVIRAL VECTOR-BASED VACCINE FOR EMERGING VIRUSES

Coronavirus Vaccine

EPITOPE AND IMMUNOGEN DESIGN FOR DEVELOPMENT OF VACCINES, DIAGNOSTICS, AND IMMUNOTHERAPEUTICS

IMMUNOGENIC CONSTRUCTS AND VACCINES FOR USE IN THE PROPHYLACTIC AND THERAPEUTIC TREATMENT OF INFECTIOUS DISEASES

THERAPEUTIC INTERFERING PARTICLES FOR CORONA VIRUS

VACCINES AND RELATED METHODS

COMPOSITIONS AND METHODS FOR INCREASING VIRAL NUCLEOCAPSID PROTEIN DIMERIZATION

ENHANCED EXPRESSION VIA AUTOTRANSPORTERS

VIRAL PREPARATIONS AND METHODS FOR TREATING AND MODULATING MITOCHONDRIAL EFFECTS OF CORONAVIRUS INFECTIONS.

VIRAL PREPARATIONS AND METHODS FOR TREATING AND MODULATING MITOCHONDRIAL EFFECTS OF CORONAVIRUS INFECTIONS.

LIVE-ATTENUATED SARS-COV-2 VACCINE

Dual-Action Recombinant Vesicular Stomatitis Virus (RVSV)-Based Vaccine (DAV) Against COVID-19 and Influenza Viruses

SYNTHETIC MODIFIED VACCINIA ANKARA (SMVA) BASED CORONAVIRUS VACCINES

CHEMICAL SCREEN OF MODULATORS FOR VACCINE ADJUVANTS

CORONAVIRUS VACCINES

COMPOSITIONS OF LIPID NANOPARTICLES FOR PLASMID DNA DELIVERY TO THE LIVER AND METHODS FOR PREPARING THE SAME

PSEUDOTYPED LENTIVIRAL VECTORS

Vaccination targeting intracellular pathogens

COMBINATION OF EPITOPES AND USE THEREOF, VACCINE CONSTRUCT, METHOD OF INDUCING AN IMMUNE RESPONSE, METHOD FOR THE IDENTIFICATION OF EPITOPES

RE-FOCUSING PROTEIN BOOSTER IMMUNIZATION COMPOSITIONS AND METHODS OF USE THEREOF

PATHOGEN-LIKE ANTIGEN-BASED VACCINE AND PREPARATION METHOD THEREFOR

SARS-CoV-2 Virus-Like Particles

S-RBD Trimer Protein Vaccine for Novel Coronavirus and Preparation Method and Application Therefor

MODIFIED CORONAVIRUS S PROTEIN

NOVEL PEPTIDE CONJUGATE VACCINES

ONE-TO-STOP ATTENUATED SARS-COV-2 VIRUS

LIVE ATTENUATED SARS-COV-2 AND A VACCINE MADE THEREOF

MRNA VACCINE COMPOSITION

VACCINE AGAINST INFECTIOUS BRONCHITIS

MODRNA-BASED CAS ENDONUCLEASE AND BASE EDITOR AND USES THEREOF

MULTIVALENT PARTICLES COMPOSITIONS AND METHODS OF USE

IMMUNOSTIMULATORY PREPARATION AND COSMETIC, FOOD, FEED ADDITIVE, AND QUASI-PHARMACEUTICAL PRODUCT CONTAINING THE IMMUNOSTIMULATORY PREPARATION

MULTIVALENT DISPLAY ON ENVELOPED PARTICLES WITH HUMAN OLIGOMERIZATION DOMAINS

NUCLEIC ACID CONSTRUCT AND USE THEREOF

CHIMERIC NUCLEOTIDE SEQUENCE, VECTOR FOR EXPRESSION IN MAMMALS, RNA VACCINE, CHIMERIC FUSION PROTEIN, USE IN THE PRODUCTION OF A VACCINE AGAINST CORONAVIRUS

NOVEL PROTEIN AND NUCLEIC ACID SEQUENCES FOR COVID-19 VACCINES

mRNA vaccine for porcine Deltacoronavirus, preparation method and application thereof

Replicon Compositions and Methods of Using Same for the Treatment of Diseases

COMPOSITION COMPRISING ENGINEERED PLANT-DERIVED EXTRACELLULAR VESICLES AND USE THEREOF AS A VACCINE

RECOMBINANT CHIMERIC ADENOVIRAL VECTOR SUBSTITUTED BY KNOB GENE OF CHIMPANZEE ADENOVIRUS SEROTYPE 6, AND APPLICATION THEREOF

CYTOLYTIC T CELL IMMUNOTHERAPY FOR HIGHLY PATHOGENIC CORONAVIRUSES

TREATMENT OF CANCER USING MRNA-MEDIATED VIRUS VACCINATION ANTIGENS DELIVERED BY ATTENUATED BACTERIA

NOVEL NUCLEIC ACID MOLECULE

VACCINE COMPOSITION FOR NOVEL CORONAVIRUS INFECTION

RECOMBINANT ROTAVIRUS EXPRESSING EXOGENOUS PROTEIN AND USES THEREOF

SYSTEM FOR PRODUCING AND DELIVERING CONTACTLESS VETERINARY PASSIVE IMMUNIZATION

COMPOSITIONS AND METHODS FOR MUCOSAL VACCINATION AGAINST SARS-COV-2

DUAL FUNCTION ANTIGEN BINDING MOLECULES

STABILIZED SPIKE PROTEIN AND METHOD OF USE THEREOF AS A CORONAVIRUS DISEASE 2019 (COVID-19) VACCINE

RECOMBINANT PLASMID, IMMUNOGENIC COMPOSITION, KIT AND USES THEREOF

COMPOSITIONS AND METHODS RELATED TO EXTRACELLULAR VESICLE THERAPEUTIC DELIVERY PLATFORM

CORONAVIRUS VACCINE

VIRUS-LIKE PARTICLE STABLY EXPRESSED BY ANIMAL CELLS AS VACCINE ANTIGEN AGAINST COVID-19 AND INFLUENZA VIRUS

GENE DELIVERY SYSTEM

SURFACE CONJUGATION TO POLY(AMINE-CO-ESTER) NANOPARTICLES FOR TARGETING TO CELLS AND TISSUES

Anti COVID-19 Therapies targeting nucleocapsid and spike proteins

SARS-CoV-2 VACCINE COMPOSITIONS

VACCINE COMPOSITION COMPRISING AN ANTIGEN AND A TLR3 AGONIST

SYNTHETIC MODIFIED VACCINIA ANKARA (SMVA) BASED CORONAVIRUS VACCINES

MODIFIED SELF-REPLICATING MRNA

ALPHAVIRUS REPLICON ENCODING CHIMERIC SARS-COV-2 RECEPTOR BINDING DOMAINS

RECOMBINANT NEWCASTLE DISEASE VIRUSES AND IMMUNOGENIC COMPOSITIONS FOR USE IN IMMUNIZING AGAINST SARS-COV-2 OMICRON VARIANT

RECOMBINANT FUSION PROTEIN DERIVED FROM HR REGION OF S2 PROTEIN OF SARS-COV-2 AND APPLICATION OF RECOMBINANT FUSION PROTEIN

RNA VACCINE LIPID NANOPARTICLES

IMPROVED CHIMERIC POLYPEPTIDES AND USES THEREOF

Novel Peptides and Vaccines Capable of Eliciting Protective Immunity Against SARS-CoV-2

POXVIRUS-BASED VECTORS PRODUCED BY NATURAL OR SYNTHETIC DNA AND USES THEREOF

SECRETION-OPTIMIZED DE NOVO DESIGNED PROTEIN NANOPARTICLES FOR EUKARYOTIC EXPRESSION AND GENETIC DELIVERY

POLYNUCLEOTIDE VACCINES AND METHODS OF USING THE SAME

Engineered Probiotic Delivery System for Anti-SARS-COV-2 Treatment and Immunity Against Viruses

MODIFIED SPIKE PROTEINS AND USES THEREOF

TREATMENT AND PREVENTION OF CONDITIONS ASSOCIATED WITH RESPIRATORY DISEASES

CELL ENTRY-MODULATING AGENTS AND USES THEREFOR

LIPID NANOPARTICLES FOR TARGETED DELIVERY OF MRNA

BIOLOGICALLY PRODUCED NUCLEIC ACID FOR VACCINE PRODUCTION

VACCINE CONSTRUCT AND USES THEREOF

CORONAVIRUS ANTIGEN VARIANTS

FUSION PROTEIN AND USE THEREOF

CORONAVIRUS VACCINE COMPOSITIONS AND METHODS

INTERFERON-PRODUCING UNIVERSAL SARBECOVIRUS VACCINES, AND USES THEREOF

ATTENUATED SARS-COV-2

SIGNAL SEQUENCES FOR NUCLEIC ACID VACCINES

NOVEL REOVIRUS-BASED VACCINE PLATFORM AND USE THEREOF

ALUMINUM NANOCRYSTAL DELIVERY SYSTEM, AND SELF-ASSEMBLED PARTICLE ADJUVANT VACCINE BASED ON BINDING OF ALUMINUM NANOCRYSTAL DELIVERY SYSTEM AND VACCINE ANTIGEN MOLECULE

AUTOLOGOUS CELL BASED SARS-COV-2 VACCINES

NANOSTRUCTURE-BASED VECTOR SYSTEM FOR BACTERIAL AND VIRAL ANTIGENS

TETANUS VACCINE PLATFORM FOR EMBEDDING COVID-19 VACCINE

INTRANASAL IMMUNOGENIC COMPOSITIONS

COMPOSITIONS AND METHODS FOR FcRn-TARGETED INTRANASAL CORONAVIRUS VACCINATION

BETA-CORONAVIRUS FUSION RECOMBINANT PROTEIN, AND PREPARATION METHOD AND APPLICATION THEREOF

COMPOSITIONS CONTAINING POLYNUCLEOTIDE AMPHIPHILES AND METHODS OF USE THEREOF

USE OF NOVEL POLYMER FOR PREVENTING SARS-COV-2

Pan-Coronavirus Immunogenic Compositions

STABILIZED LIPID NANOPARTICLE MRNA COMPOSITIONS AND USES THEREOF

MEMBRANE FUSION AND IMMUNE EVASION BY THE SPIKE PROTEIN OF SARS-COV-2 DELTA VARIANT

COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF CORONAVIRUS INFECTION

Immunogenic Fusion Peptides Including FC Fragment and a Non Toxic B Subunit of AB5 Toxin

NUCLEIC ACID-LIPID NANOPARTICLE AND METHOD USING THE SAME

An Immunogenic Composition of Disease-Associated Antigens for Use in a Vaccine, Antibody Production and Immunodiagnostic Tests

FUSION POLYPEPTIDE

BETACORONA VIRUS mRNA VACCINES

BETACORONAVIRUS mRNA VACCINES

VACCINES AGAINST CORONAVIRUS AND METHODS OF USE

VACCINE COMPOSITIONS AND THEIR USE

LOW-SUGAR CORONAVIRUS VACCINE AND METHODS THEREOF

CHIMERIC PROTEIN PRODUCTION PROCESS, CHIMERIC PROTEIN, GENE, IMMUNOGENIC COMPOSITION AND USES

RECOMBINANT POLYPEPTIDES CONTAINING AT LEAST ONE IMMUNOGENIC FRAGMENT AND ANTIBODY FC REGION AND USES THEREOF

VACCINES AND RELATED METHODS

SELF-AMPLIFYING RNA COMPOSITIONS AND METHODS OF USE THEREOF

OPTIMIZED AAV-BASED VACCINE

Viral Vaccines

REVERSE PEPTIDES FROM CORONAVIRUS FOR IMMUNOGENIC PURPOSES

Recombinant RNA Molecules Comprising Untranslated Regions or Segments Encoding Spike Protein from the Omicron Strain of Severe Acute Respiratory Coronavirus-2

MRNA VACCINE

CORONAVIRUS VACCINE

SARS-COV-2 S PROTEIN POLYPEPTIDE ANTIGEN AND APPLICATION THEREOF

A MURINE CYTOMEGALOVIRUS VACCINE VECTOR FOR ADMINISTRATION IN A NON-MOUSE SUBJECT

CORONAVIRUS VACCINE COMPOSITIONS AND USES THEREOF

SARS COV-2 VACCINE, ASSOCIATED POLYNUCLEOTIDES, AND METHODS OF USE

PORCINE CORONAVIRUS VACCINES

CIRCULAR RNA VACCINES AGAINST SARS-COV-2 VARIANTS AND METHODS OF USE THEREOF

BACTERIOPHAGE LAMBDA-VACCINE SYSTEM

PORCINE EPIDEMIC DIARRHEA VIRUS STRAINS AND IMMUNOGENIC COMPOSITIONS THEREFROM

Novel chimpanzee adenovirus vector, construction method therefor, and application thereof

IBV VACCINE WITH HETEROLOGOUS DMV/1639 SPIKE PROTEIN

A SARS-COV-2 Human Parainfluenza Virus Type 3-Vectored Vaccine

PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING CORONAVIRUS INFECTION

Multicistronic Vaccine and Methods for Producing and Using the Same

Immunogenic Constructs And Vaccines For Use In The Prophylactic And Therapeutic Treatment Of Diseases Caused By SARS-CoV-2

RECOMBINANT PROTEIN FOR DISPLAYING S PROTEIN OF SARS-COV-2, RECOMBINANT VIRION, AND USE THEREOF

RECOMBINANT MULTIVALENT VACCINE

T Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof

RECOMBINANT NEWCASTLE DISEASE VIRUS EXPRESSING SPIKE PROTEIN OF SARS-COV-2 DELTA VARIANT AND USES THEREOF

RATIONALLY DESIGNED IMMUNOGENS

IMMUNOGENIC COMPOSITIONS AND THEIR USES

EXPRESSION OF THE SPIKE S GLYCOPROTEIN OF SARS-COV-2 FROM AVIAN PARAMYXOVIRUS TYPE 3 (APMV3)

METHODS OF PREVENTING, TREATING, OR REDUCING THE SEVERITY OF CORONAVIRUS DISEASE 2019 (COVID-19)

CHIMERIC BETACORONAVIRUS SPIKE POLYPEPTIDES

CORONAVIRUS VACCINE FORMULATIONS

UNIVERSAL SARBECOVIRUS VACCINES

CORONAVIRUS DERIVED RNA REPLICONS AND THEIR USE AS VACCINES

VACCINES FOR IN VIVO EXPRESSION OF NUCLEIC ACIDS AND METHODS OF USING THE SAME

METHODS OF PREVENTING, TREATING, OR REDUCING THE SEVERITY OF COVID-19 IN IMMUNOCOMPROMISED BLOOD CANCER PATIENTS

COMPOSITIONS AND METHODS FOR MODULAR VACCINES

APPLICATION OF NOVEL CORONAVIRUS VACCINE PEPTIDE AND NANOEMULSION PREPARATION THEREOF IN PREVENTION OF NOVEL CORONAVIRUS WILD AND MUTANT STRAINS

BETACORONAVIRUS ATTENUATED STRAIN

EXOSOMAL NUCLEIC ACID VACCINE COMPOSITION FOR PROTECTION AGAINST SARS-COV-2 INFECTION AND DISEASE

ANTIGEN DELIVERY PLATFORM AND METHODS OF USE

SARS-COV-2 SPIKE FUSED TO A HEPATITIS B SURFACE ANTIGEN

EXOSOME-BASED ANTIVIRAL VACCINE AND MANUFACTURING METHOD THEREOF

MRNA VACCINE DESIGN VIA THE ALTERATION OF CODON USAGE

IDENTIFICATION AND USES OF PEPTIDE SEQUENCES OF SARS-COV-2 T CELL AND B CELL EPITOPES

CORONAVIRUS FUSION PROTEIN

NOVEL METHODS OF USING ADENO-ASSOCIATED VIRUS 11 (AAV11)

UNDIRECTED MUTATED MRNA VACCINE

METHODS AND COMPOSITIONS FOR BAT IPSC PREPARATION AND USE

ORAL THERAPEUTIC VACCINE COMPOSITIONS, METHODS AND TREATMENT OF COVID

Coronavirus T Cell Epitopes and Uses Thereof

IMMUNOGENIC FUSION PROTEINS AGAINST CORONAVIRUS

A VACCINE FOR CORONAVIRUS AND INFLUENZA VIRUS, AND METHOD FOR PREPARATION THEREOF

RNA CONSTRUCTS AND USES THEREOF

RNA FORMULATIONS AND LIPIDS

NEW CORONAVIRUS VACCINE AND METHOD FOR DESIGNING AND OBTAINING A VIRUS VACCINE

VIRUS VACCINE

Immunomodulatory proteins- or targeting proteins-expressing nanovesicles, methods of preparing the nanovesicle and use thereof

PAN-HUMAN CORONAVIRUS VACCINES

MULTIVALENT VIRAL PARTICLES

FULLY SYNTHETIC, LONG-CHAIN NUCLEIC ACID FOR VACCINE PRODUCTION TO PROTECT AGAINST CORONAVIRUSES

SARS-COV-2 IMMUNIZING COMPOSITIONS AND METHODS

SARS-COV-2 VACCINE COMPOSITIONS

VIRAL-LIKE PARTICLES FOR THE TREATMENT OR PREVENTION OF AN INFECTION BY A CORONAVIRIDAE VIRUS

VACCINE COMPOSITION FOR PREVENTION AGAINST COVID-19

CORONAVIRUS VACCINE

COMBINATION HMPV/RSV RNA VACCINES

Betacoronavirus RNA vaccines

Cationic Lipid Compound and Composition for Delivery of Nucleic Acids and Use Thereof

Novel Adjuvant Compositions

Vaccine Antigen

DOUBLE STRANDED MRNA VACCINES

RIBONUCLEOPROTEIN NANOCOMPLEX VACCINES AND USES THEREOF

VACCINES AND COMPOSITIONS BASED ON SARS-COV-2 S PROTEIN

COMBINATION HMPV/RSV RNA VACCINES

SMALL MOLECULE COMPOUNDS

LYOPHILISED FORMULATIONS OF mRNA ADSORBED ONTO LIPID NANO-EMULSION PARTICLES

OPTIMIZED NUCLEOTIDE SEQUENCES ENCODING SARS-COV-2 ANTIGENS

METHOD FOR SURFACE EXPRESSION OF MEMBRANE PROTEINS THAT HAVE A CYTOPLASMIC C-TERMINAL TAIL

EFFICIENT VACCINE

COMBINATION HMPV/RSV RNA VACCINES

CORONAVIRUS AND INFLUENZA COMPOSITIONS AND METHODS FOR USING THEM

Recombinant Severe Acute Respiratory Syndrome Coronavirus 2 Rbd Trimer Protein Vaccine Capable Of Generating Broad-Spectrum Cross Neutralization Activity, and Preparation Method and Use Thereof

PLANT-BASED COVID-19 VARIANT RECOMBINANT SPIKE PROTEIN EXPRESSION VECTOR AND RECOMBINANT PROTEIN USING SAME

SARS-COV-2 SUBUNIT VACCINE

CONJUGATED PROTEIN MONOMER CARRYING PEPTIDE DERIVED FROM PATHOGENIC MICROORGANISM COMPATIBLE WITH MHC MOLECULE, AGGREGATE OF SAID MONOMERS, COMPONENT VACCINE CONTAINING SAID AGGREGATE AS ACTIVE INGREDIENT, AND METHOD FOR ACQUIRING INFORMATION ON SECRETION OF PHYSIOLOGICALLY ACTIVE SUBSTANCE AFTER IMMUNIZATION

FOLLICULAR HELPER T (TFH) CELLS SPECIFIC TO SARS-COV-2 VIRUS

REVERSE GENETICS-BASED COMPOSITIONS OF ATTENUATED RECOMBINANT SARS-COV-2

COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19

VACCINES FOR CORONAVIRUS PREVENTION AND TREATMENT

DEOPTIMIZED SARS-COV-2 VARIANTS AND METHODS AND USES THEREOF

ADAPTER POLYPEPTIDES AND METHODS OF USING THE SAME

A DNA PLASMID SARS-CORONA VIRUS-2/COVID-19 VACCINE

COMPOSITIONS AND METHODS OF MRNA THERAPEUTICS

RECOMBINANT MEASLES VIRUS

INACTIVATED SARS-COV-2 VIRUS VACCINE

MODIFIED PIV5 VACCINE VECTORS: METHODS OF MAKING AND USES

SELF-ASSEMBLING INSECT FERRITIN NANOPARTICLES

MRNA VACCINES ENCODING FLEXIBLE CORONAVIRUS SPIKE PROTEINS

Attenuated Porcine Epidemic Diarrhea Virus

CORONAVIRUS VACCINES

Self-Amplifying RNA-Based VLP Vaccines

VACCINE

NON-VIRAL DNA VECTORS FOR VACCINE DELIVERY

POLYPEPTIDES, COMPOSITIONS, AND THEIR USE TO TREAT OR LIMIT DEVELOPMENT OF AN INFECTION

PHARMACEUTICAL COMPOSITION FOR TREATMENT OF COVID-19 AND RELATED PATHOLOGIES

COVID-19 VACCINES WITH TOCOPHEROL-CONTAINING SQUALENE EMULSION ADJUVANTS

BROAD-SPECTRUM MULTI-ANTIGEN PAN-CORONAVIRUS VACCINE

Peptide VLP-Based Vaccines

HUMAN CORONAVIRUS 229E DERIVED PEPTIDES

METHODS, KITS, AND APPROACHES FOR VIRAL VACCINES

EXPRESSION OF SARS-COV PROTEINS, NUCLEIC ACID CONSTRUCTS, VIRUS LIKE PROTEINS (VLPS) AND METHODS RELEVANT THERETO

POLYPEPTIDE FRAGMENTS, IMMUNOGENIC COMPOSITION AGAINST SARS-CoV-2, AND IMPLEMENTATIONS THEREOF

COMPOSITIONS AND METHODS TO INCREASE CORONAVIRUS IMMUNE RESPONSE

TLR7 AGONIST CONJUGATED PEPTIDE-BASED NOVEL CORONAVIRUS NANOEMULSION VACCINE AND PREPARATION THEREOF

VACCINE FOR PREVENTION OR TREATMENT OF VIRAL INFECTION

AMINO ACIDS, NUCLEOTIDES AND VECTORS EXPRESSING THE SAME AND USES THEREOF IN PREVENTING SARBECOVIRUS INFECTION

GENETICALLY MODIFIED CLOSTRIDIUM STRAINS EXPRESSING RECOMBINANT ANTIGENS AND USES THEREOF

Coronavirus Constructs and Vaccines

CORONAVIRUS SPIKE PROTEIN DESIGNS, COMPOSITIONS AND METHODS FOR THEIR USE

LIVE-ATTENUATED VIRUS VACCINE

SARS-COV-2 RBD CONSTRUCTS

Use of Ectromelia Virus for Cancer Immunotherapy and Vaccines

Vaccines for the Treatment and Prevention of Zoonotic Infections

COMBINATIONS OF VIRAL PROTEINS, PEPTIDE SEQUENCES, EPITOPES, AND METHODS AND USES THEREOF

PANCORONAVIRUS VACCINES

SARS-COV-2 MULTI-EPITOPE VACCINES

METHOD FOR MODELING CYCLIC 3D EPITOPES TO BE USED IN THE DEVELOPMENT OF VACCINES

Methods for Monoclonal Antibody Generation

ARTIFICIAL ADJUVANT VECTOR CELL CAPABLE OF INDUCING IMMUNE RESPONSE TO CORONAVIRUS, PHARMACEUTICAL COMPOSITION CONTAINING SAID CELL, AND USE APPLICATIONS OF SAID CELL AND SAID PHARMACEUTICAL COMPOSITION

COMPOSITIONS AND METHODS FOR MUCOSAL VACCINATION AGAINST SARS-COV-2

RECOMBINANT VIRAL CLASS I FUSION PROTEINS AND USES THEREOF

Highly Attenuated Replication-Competent Recombinant Poxvirus As A Vaccine Platform And Methods Of Use

IMMUNOGENIC COMPOSITIONS

MODIFIED CORONAVIRUS STRUCTURAL PROTEIN

Vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus

RESPIRATORY VIRUS COMBINATION VACCINES

POLYNUCLEOTIDES CAPABLE OF ENHANCED PROTEIN EXPRESSION AND USES THEREOF

ENGINEERED INFLUENZA VIRUSES EXPRESSING SARS-COV-2 ANTIGENS, VACCINES AND METHODS OF MAKING AND USING THE SAME

RHABDOVIRUS-NEGATIVE SPODOPTERA FRUGIPERDA INSECT CELL LINE, AND SCREENING, IDENTIFICATION AND APPLICATION THEREOF

Methods for Providing a Vaccine

A VACCINE ADJUVANT FOR INFECTIOUS DISEASES

ORAL COMPOSITIONS AND USE OF SAME IN VACCINATION

IMMUNOGENIC COMPOSITIONS AND METHODS FOR IMMUNIZATION AGAINST VARIANTS OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2)

RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING SARS-COV-2 SPIKE PROTEIN AND ITS USE

STABILIZED CORONAVIRUS SPIKE PROTEIN FUSION PROTEINS

MODIFIED VIRUS-LIKE PARTICLES OF BACTERIOPHAGE AP205